congenital disorder of glycosylation type Ia
In congenital disorder of glycosylation type Ia, PMM2 activity is compromised; thus, PMI inhibition is a potential strategy for the development of therapeutics.
In <span class="disease" id="21539312-2-3-47">congenital disorder of glycosylation type Ia</span>, <span class="gene" id="21539312-2-49-53">PMM2</span> activity is compromised; thus, PMI inhibition is a potential strategy for the development of therapeutics.